Edition:
United States

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

3.35USD
25 May 2017
Change (% chg)

-- (--)
Prev Close
$3.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
18,190
52-wk High
$4.45
52-wk Low
$2.12

LIFE.OQ

Chart for LIFE.OQ

About

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)

Overall

Beta: --
Market Cap(Mil.): $83.32
Shares Outstanding(Mil.): 23.81
Dividend: --
Yield (%): --

Financials

  LIFE.OQ Industry Sector
P/E (TTM): -- 138.86 17.42
EPS (TTM): -2.33 -- --
ROI: -68.49 2.17 -5.45
ROE: -73.01 0.04 -4.73

BRIEF-aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56

* aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56

May 11 2017

BRIEF-Atyr Pharma announces promising top-line results from Resolaris

* Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy

Apr 24 2017

BRIEF-aTyr Pharma appoints of Timothy P. Coughlin to its board

* aTyr Pharma announces appointment of TIMOTHY P. COUGHLIN to its board of directors Source text for Eikon: Further company coverage:

Apr 10 2017

BRIEF-aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53

* Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018

Mar 16 2017

BRIEF-Atyr Pharma reports issuance of U.S. patent that extends patent protection of physiocrines

* Atyr Pharma announces issuance of U.S. patent that extends patent protection of physiocrines derived from 20 out of 20 human TRNA synthetases Source text for Eikon: Further company coverage:

Mar 15 2017

BRIEF-Atyr Pharma receives EMA orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris

* Atyr Pharma receives ema orphan drug designation for the treatment of limb girdle muscular dystrophy with resolaris™ Source text for Eikon: Further company coverage:

Mar 03 2017

BRIEF-Atyr Pharma receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris

* Atyr Pharma Receives U.S. FDA orphan drug designation for the treatment of limb girdle muscular dystrophy with Resolaris™ Source text for Eikon: Further company coverage:

Feb 28 2017

BRIEF-Ecor1 Capital reports 8.3 pct passive stake in Atyr Pharma

* Ecor1 Capital LLC reports 8.3 percent passive stake in Atyr Pharma Inc as of Jan 18 - SEC filing Source text: (http://bit.ly/2kkPDsu) Further company coverage:

Jan 30 2017

BRIEF-FDA grants fast track designation for aTyr's Resolaris

* Fda grants fast track designation for aTyr's Resolaris to treat limb girdle muscular dystrophy 2b and removes partial clinical hold for Resolaris

Jan 18 2017

More From Around the Web

Earnings vs. Estimates